|
|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Brigham and Women's Hospital Beth Israel Deaconess Medical Center Genentech |
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00658697 |
In this research study, we are looking to see how Avastin works in combination with docetaxel and hormone therapy for men who have a rising PSA after treatment of their prostate cancer with surgery or radiation.
Condition | Intervention | Phase |
Prostate Cancer |
Drug: Docetaxel Drug: Avastin Drug: Lupron or Zoladex Drug: Bicalutamide |
Phase II |
MedlinePlus related topics: | Cancer Prostate Cancer |
ChemIDplus related topics: | Docetaxel Bevacizumab Goserelin Leuprolide acetate Leuprolide Bicalutamide |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Efficacy Study |
Official Title: | A Phase II Trial of Avastin, Docetaxel and Androgen Deprivation Followed by Continued Avastin and Androgen Deprivation for Men With a Rising PSA After Local Therapy |
Estimated Enrollment: | 42 |
Study Start Date: | April 2008 |
Estimated Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Mary-Ellen Taplin, MD | 617-632-5092 | |
Contact: Gina Scibelli | 617-632-5598 |
United States, Massachusetts | |||||
Dana-Farber Cancer Institute | Recruiting | ||||
Boston, Massachusetts, United States, 02115 | |||||
Principal Investigator: Mary-Ellen Taplin, MD | |||||
Beth Israel Deaconess Medical Center | Recruiting | ||||
Boston, Massachusetts, United States, 02115 | |||||
Principal Investigator: Glenn Bubley, MD |
Dana-Farber Cancer Institute |
Brigham and Women's Hospital |
Beth Israel Deaconess Medical Center |
Genentech |
Principal Investigator: | Mary-Ellen Taplin, MD | Dana-Farber Cancer Institute |
Responsible Party: | Dana-Farber Cancer Institute ( Mary-Ellen Taplin, MD ) |
Study ID Numbers: | 08-004 |
First Received: | April 9, 2008 |
Last Updated: | April 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00658697 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|